Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase 3 - Partnering Implications
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(256)
•••
Comment by GameChangerBeton May 26, 2021 12:25pm
164 Views
Post# 33268120

RE:Phase 3 - Partnering Implications

RE:Phase 3 - Partnering Implications
Harper75 wrote: Perhaps a change in thread...

Antibe hasn't been shy about courting a Phs3 Partner, we all also talk about it.

Any thoughts to the implications on who Antibe eventually partners with?  Is the market assuming that one of the giants will step up and if they do not, is that seen as a negative catalyst.  Is there any partnering baked into the SP right now?  



[/quote
The concentration is now on Europe and the US, with Japan soon. They are a week away from finishing the contacting of the names on their target list for Europe/US.

I would argue that no pricing in of any potential partnerships has occured in the stock.
Which really leaves the runway wide open for a big price move and revaluation.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities